Download PDF
Semin Vasc Med 2003; 03(1): 061-068
DOI: 10.1055/s-2003-38333
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Changes of Hemostatic Variables during Oral Contraceptive Use

Guido Tans1 , Bonno N. Bouma2 , Harry R. Büller3 , Jan Rosing1
  • 1Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
  • 2Thrombosis and Haemostasis Laboratory, Department of Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
  • 3Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
Further Information

Publication History

Publication Date:
27 March 2003 (online)

    Permissions and Reprints

ABSTRACT

The use of oral contraceptives (OCs) has been known for many years to affect significantly almost all hemostatic parameters, but the challenge to relate these changes in a meaningful way to OC-induced increased venous thrombotic risk has not been met. New insights indicate that at least part of the answer can be found in the net effect of OC use on the efficacy with which the protein C pathway down-regulates thrombin formation. During OC use the (blood) plasma of a woman becomes resistant to the anticoagulant action of activated protein C (APC). The extent of this so-called acquired APC resistance as determined in a thrombin generation-based assay correlates remarkably well with the risk increases observed in clinical studies. Recent evidence indicates that the prothrombotic effect of the estrogen component ethinylestradiol in combined OC is counteracted by the progestagen component present in these preparations and that third-generation progestagens such as desogestrel or gestodene are less efficient with respect to this than the second-generation progestagen levonorgestrel.

KEYWORDS

Oral contraceptives - progestagen-only - thrombosis - hemostasis - APC resistance

REFERENCES

  • 1 Jordan W M. Pulmonary embolism.  Lancet . 1961;  2 1146-1147
    PubMedGoogle Scholar
  • 2 Hannaford P C, Owen-Smith V. Using epidemiological data to guide clinical practice: review of studies on cardiovascular disease and use of combined oral contraceptives.  Br Med J . 1998;  316 984-987
    PubMedGoogle Scholar
  • 3 WHO. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.  Lancet . 1995;  346 1582-1588
    PubMedGoogle Scholar
  • 4 Farmer R D, Lawrenson R A, Thompson C R, Kennedy J G, Hambleton I R. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.  Lancet . 1997;  349 83-88
    CrossrefPubMedGoogle Scholar
  • 5 Vandenbroucke J P, Helmerhorst F M, Bloemenkamp K WM, Rosendaal F R. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation.  Am J Obstet Gynecol . 1997;  177 887-891
    PubMedGoogle Scholar
  • 6 Jick H, Kaye J A, Vasilakis-Scaramozza C, Jick S S. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995; cohort and case-control analysis.  BMJ . 2000;  321 1190-1195
    CrossrefPubMedGoogle Scholar
  • 7 Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables.  Thromb Haemost . 1997;  78 315-326
    PubMedGoogle Scholar
  • 8 Winkler U H. Blood coagulation and oral contraceptives. A critical review.  Contraception . 1998;  57 203-209
    CrossrefPubMedGoogle Scholar
  • 9 Winkler U H. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.  Am J Obstet Gynecol . 1998;  179 S51-S61
    CrossrefPubMedGoogle Scholar
  • 10 Kluft C. Effects on haemostasis variables by second and third generation combined oral contraceptives: a review of directly comparative studies.  Curr Med Chem . 2000;  7 585-591
    PubMedGoogle Scholar
  • 11 Koster T, Rosendaal F R, Reitsma P H. et al . Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms-the Leiden Thrombophilia Study (LETS).  Thromb Haemost . 1994;  71 719-722
    PubMedGoogle Scholar
  • 12 Dahlback B, Carlsson M, Svensson P J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.  Proc Natl Acad Sci U S A . 1993;  90 1004-1008
    PubMedGoogle Scholar
  • 13 Svensson P J, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis.  N Engl J Med . 1994;  330 517-522
    CrossrefPubMedGoogle Scholar
  • 14 Voorberg J, Roelse J, Koopman R. et al . Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V.  Lancet . 1994;  343 1535-1536
    CrossrefPubMedGoogle Scholar
  • 15 Bertina R M, Koeleman B P, Koster T. et al . Mutation in blood coagulation factor V associated with resistance to activated protein C.  Nature . 1994;  369 64-67
    CrossrefPubMedGoogle Scholar
  • 16 Greengard J S, Sun X, Xu X. et al . Activated protein C resistance caused by Arg506Gln mutation in factor Va.  Lancet . 1994;  343 1361-1362
    PubMedGoogle Scholar
  • 17 Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.  Ann Intern Med . 1999;  130 643-650
    PubMedGoogle Scholar
  • 18 de Visser C M, Rosendaal F R, Bertina R M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis.  Blood . 1999;  93 1271-1276
    PubMedGoogle Scholar
  • 19 Rosing J, Tans G, Nicolaes G AF. et al . Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.  Br J Haematol . 1997;  97 233-238
    CrossrefPubMedGoogle Scholar
  • 20 Olivieri O, Friso S, Manzato F. et al . Resistance to activated protein C in healthy women taking oral contraceptives.  Br J Haematol . 1995;  91 465-470
    PubMedGoogle Scholar
  • 21 Henkens C M, Bom V J, Seinen A J, van der Meer J. Sensitivity to activated protein C; influence of oral contraceptives and sex.  Thromb Haemost . 1995;  73 402-404
    PubMedGoogle Scholar
  • 22 Vandenbroucke J P, Rosendaal F R. End of the line for "third-generation-pill" controversy?.  Lancet . 1997;  349 1113-1114
    CrossrefPubMedGoogle Scholar
  • 23 Spitzer W O. The 1995 pill scare revisited: anatomy of a non-epidemic.  Hum Reprod . 1997;  12 2347-2357
    CrossrefPubMedGoogle Scholar
  • 24 Spitzer W O. Bias versus causality: interpreting recent evidence of oral contraceptive studies.  Am J Obstet Gynecol . 1998;  179 S43-S50
    CrossrefPubMedGoogle Scholar
  • 25 Winkler U H. Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism.  Contraception . 2000;  62 11S--38S
    PubMedGoogle Scholar
  • 26 Heinemann L AJ, Spitzer W O, Winkler U H. Scientific problems with a noncausal artifact.  Am J Obstet Gynecol . 1998;  178 1105-1106
    PubMedGoogle Scholar
  • 27 Kluft C. A rebuttal-oral contraceptives and venous thrombosis: reply.  Thromb Haemost . 2001;  85 934-936
    PubMedGoogle Scholar
  • 28 Kluft C. Renewed interest in haemostasis changes induced by oral contraceptives (OCs).  Thromb Haemost . 2000;  84 1-3
    PubMedGoogle Scholar
  • 29 Rosing J, Middeldorp S, Curvers J. et al . Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.  Lancet . 1999;  354 2036-2040
    CrossrefPubMedGoogle Scholar
  • 30 Meijers J C, Middeldorp S, Tekelenburg W. et al . Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.  Thromb Haemost . 2000;  84 9-14
    PubMedGoogle Scholar
  • 31 Middeldorp S, Meijers J C, van den Ende E A. et al . Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.  Thromb Haemost . 2000;  84 4-8
    PubMedGoogle Scholar
  • 32 Tans G, Curvers J, Middeldorp S. et al . A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.  Thromb Haemost . 2000;  84 15-21
    PubMedGoogle Scholar
  • 33 Bajzar L, Manuel R, Nesheim M E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor.  J Biol Chem . 1995;  270 14477-14484
    CrossrefPubMedGoogle Scholar
  • 34 Redlitz A, Tan A K, Eaton D L, Plow E F. Plasma carboxypeptidases as regulators of the plasminogen system.  J Clin Invest . 1995;  96 2534-2538
    CrossrefPubMedGoogle Scholar
  • 35 Wang W, Boffa M B, Bajzar L, Walker J B, Nesheim M E. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor.  J Biol Chem . 1998;  273 27176-27181
    CrossrefPubMedGoogle Scholar
  • 36 Heeb M J, Rosing J, Bakker H M. et al . Protein S binds to and inhibits factor Xa.  Proc Natl Acad Sci U S A . 1994;  91 2728-2732
    PubMedGoogle Scholar
  • 37 Hackeng T M, van 't Veer C, Meijers J C, Bouma B N. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa.  J Biol Chem . 1994;  269 21051-21058
    PubMedGoogle Scholar
  • 38 Varadi K, Rosing J, Tans G. et al . Factor V enhances the cofactor function of protein S in the APC- mediated inactivation of factor VIII: influence of the factor VR506Q mutation.  Thromb Haemost . 1996;  76 208-214
    PubMedGoogle Scholar
  • 39 Varadi K, Rosing J, Tans G, Schwarz H P. Influence of factor V and factor Va on APC-induced cleavage of human factor VIII.  Thromb Haemost . 1995;  73 730-731
    PubMedGoogle Scholar
  • 40 Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa.  J Biol Chem . 1994;  269 18735-18738
    PubMedGoogle Scholar
  • 41 Kluft C, de Maat P M, Heinemann L A, Spannagl M, Schramm W. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation.  Lancet . 1999;  354 832-833
    PubMedGoogle Scholar
  • 42 Kemmeren J M, Algra A, Meijers J C, Bouma B N, Grobbee D E. Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation.  Blood Coagul Fibrinolysis . 2002;  13 373-381
    CrossrefPubMedGoogle Scholar
  • 43 Kemmeren J M, Algra A, Meijers J C, Bouma B N, Grobbee D E. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.  Thromb Haemost . 2002;  87 199-205
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Kemmeren J M, Algra A, Meijers J C. et al . Effects of second and third generation oral contraceptives and their respective progestagens on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial (submitted for publication). 
    PubMedGoogle Scholar
  • 45 Curvers J, Thomassen M C, Nicolaes G A. et al . Acquired APC resistance and oral contraceptives: differences between two functional tests.  Br J Haematol . 1999;  105 88-94
    CrossrefPubMedGoogle Scholar
  • 46 Curvers J, Thomassen M C, Rimmer J. et al . Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.  Thromb Haemost . 2002;  88 5-11
    PubMedGoogle Scholar
  • 47 Oral contraceptives in the nineties: metabolic aspects-facts and fiction. First European Conference on Sex Steroids and Metabolism. Esbjerg, Denmark, May 18-20, 1989.  Am J Obstet Gynecol . 1990;  163 273-446
    PubMedGoogle Scholar
  • 48 Consensus Development Meeting: metabolic aspects of oral contraceptives of relevance for cardiovascular diseases.  Am J Obstet Gynecol . 1990;  162 1335-1337
    PubMedGoogle Scholar
  • 49 Vandenbroucke J P, Rosing J, Bloemenkamp K W. et al . Oral contraceptives and the risk of venous thrombosis.  N Engl J Med . 2001;  344 1527-1535
    CrossrefPubMedGoogle Scholar
  • 50 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood . 1996;  88 3698-3703
    CrossrefPubMedGoogle Scholar
  • 51 van Hylckama Vlieg A, van der Linden K I, Bertina R M, Rosendaal F R. High levels of factor IX increase the risk of venous thrombosis.  Blood . 2000;  95 3678-3682
    PubMedGoogle Scholar
  • 52 Meijers J C, Tekelenburg W L, Bouma B N, Bertina R M, Rosendaal F R. High levels of coagulation factor XI as a risk factor for venous thrombosis.  N Engl J Med . 2000;  342 696-701
    CrossrefPubMedGoogle Scholar
  • 53 Comp P C, Nixon R R, Cooper M R, Esmon C T. Familial protein S deficiency is associated with recurrent thrombosis.  J Clin Invest . 1984;  74 2082-2088
    CrossrefPubMedGoogle Scholar
  • 54 Comp P C, Esmon C T. Recurrent venous thromboembolism in patients with a partial deficiency of protein S.  N Engl J Med . 1984;  311 1525-1528
    CrossrefPubMedGoogle Scholar
  • 55 Griffin J H, Evatt B, Zimmerman T S, Kleiss A J, Wideman C. Deficiency of protein C in congenital thrombotic disease.  J Clin Invest . 1981;  68 1370-1373
    CrossrefPubMedGoogle Scholar
  • 56 Schwarz H P, Fischer M, Hopmeier P, Batard M A, Griffin J H. Plasma protein S deficiency in familial thrombotic disease.  Blood . 1984;  64 1297-1300
    PubMedGoogle Scholar
  • 57 Koster T, Rosendaal F R, de Ronde H. et al . Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.  Lancet . 1993;  342 1503-1506
    CrossrefPubMedGoogle Scholar
  • 58 Zöller B, Hillarp A, Berntorp E, Dahlback B. Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis.  Annu Rev Med . 1997;  48 45-58
    CrossrefPubMedGoogle Scholar
  • 59 Greaves M, Preston F E. Rebuttal to: oral contraceptives and venous thromboembolism.  Thromb Haemost . 2001;  85 932-936
    PubMedGoogle Scholar
  • 60 Tans G, Rosendaal F R, Curvers J. et al . APC resistance determined with the endogenous thrombin potential is associated with venous thrombosis: a blinded clinical evaluation.  Thromb Haemost . 1999;  Suppl 202-203
    PubMedGoogle Scholar
  • 61 Heinemann L AJ, Assmann A, Spannagl M. et al . Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.  Contraception . 1998;  58 321-322
    CrossrefPubMedGoogle Scholar
  • 62 Thomassen M L G D C, Curvers J, Rimmer J E. et al . Influence of hormone replacement therapy, oral contraceptives and pregnancy on APC-resistance.  Thromb Haemost . 1999;  Suppl 770-771
    PubMedGoogle Scholar
  • 63 Jick H, Jick S S, Gurewich V, Myers M W, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.  Lancet . 1995;  346 1589-1593
    CrossrefPubMedGoogle Scholar
  • 64 Bloemenkamp K WM, Rosendaal F R, Helmerhorst F M, Buller H R, Vandenbroucke J P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen.  Lancet . 1995;  346 1593-1596
    CrossrefPubMedGoogle Scholar
  • 65 Quehenberger P, Loner U, Kapiotis S. et al . Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.  Thromb Haemost . 1996;  76 729-734
    PubMedGoogle Scholar